Business Description
ProQR Therapeutics NV
ISIN : NL0010872495
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.14 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 0.7 | |||||
Debt-to-EBITDA | -0.93 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.59 | |||||
Beneish M-Score | 0.11 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 31.8 | |||||
3-Year EPS without NRI Growth Rate | 26 | |||||
3-Year Book Growth Rate | -26.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 40.67 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 100 | |||||
6-1 Month Momentum % | 33.33 | |||||
12-1 Month Momentum % | 33.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.33 | |||||
Quick Ratio | 2.33 | |||||
Cash Ratio | 2.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.5 | |||||
Shareholder Yield % | 0.87 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -167.84 | |||||
Net Margin % | -134.57 | |||||
FCF Margin % | -187.92 | |||||
ROE % | -67 | |||||
ROA % | -19.2 | |||||
ROIC % | -60.94 | |||||
ROC (Joel Greenblatt) % | -133.97 | |||||
ROCE % | -24 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 11.22 | |||||
PB Ratio | 7.88 | |||||
Price-to-Tangible-Book | 7.86 | |||||
EV-to-EBIT | -8.79 | |||||
EV-to-EBITDA | -10.1 | |||||
EV-to-Revenue | 10.73 | |||||
EV-to-Forward-Revenue | 17.16 | |||||
EV-to-FCF | -5.56 | |||||
Price-to-Net-Current-Asset-Value | 19.05 | |||||
Price-to-Net-Cash | 26.67 | |||||
Earnings Yield (Greenblatt) % | -11.37 | |||||
FCF Yield % | -13.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
ProQR Therapeutics NV Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 349.75 | ||
EPS (TTM) (MXN) | -5.715 | ||
Beta | 0.98 | ||
Volatility % | 33.33 | ||
14-Day RSI | 100 | ||
14-Day ATR (MXN) | 0.002876 | ||
20-Day SMA (MXN) | 36 | ||
12-1 Month Momentum % | 33.33 | ||
52-Week Range (MXN) | 27 - 36 | ||
Shares Outstanding (Mil) | 105.91 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ProQR Therapeutics NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ProQR Therapeutics NV Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
ProQR Therapeutics NV Frequently Asked Questions
What is ProQR Therapeutics NV(MEX:PRQR)'s stock price today?
When is next earnings date of ProQR Therapeutics NV(MEX:PRQR)?
Does ProQR Therapeutics NV(MEX:PRQR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |